Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

Osteoarthritis of the Knee Clinical Trial

Official title:

A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01111045
• Other study ID #: 09-OA-002
• Status: Completed
• Phase: Phase 2
• First received: April 23, 2010
• Last updated: January 30, 2012
• Start date: April 2010
• Est. completion date: August 2011

Study information

• Verified date: January 2012
• Source: Stryker Biotech
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7 for the treatment of osteoarthritis of the knee.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 355
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and pain on the majority of days in the last 30 days. Symptoms must include knee joint pain.

• A male or female adult age >40 years

• female subjects of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test on the day of injection

• Radiographic evidence of at least one tibiofemoral osteophyte and Osteoarthritis Research Society International (OARSI) Atlas joint space narrowing grade of 1 or 2 in the index knee

• WOMAC pain score of >8 at screening and baseline

• Able to comply with the study and give informed consent

• Able to read, write and understand English

Exclusion Criteria:

• A requirement for treatment with opioids for pain relief.

• Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hours and acetaminophen for 24 hours prior to pain assessments during the study. Subjects taking low dose aspirin for cardiovascular health may remain on their stable dose throughout the study.

• Using a handicap assistance device (i.e., cane, walker) >50% of the time.

• Undergoing new physical therapy or participating in a weight loss or exercise program that has not been stable for at least 3 months prior to screening visit 1 and will not remain stable during their participation in the study.

• History of arthroscopic or open surgery to the index knee in the past 12 months or planned surgery during study.

• History of joint replacement surgery (index knee).

• Received corticosteroid, short acting hyaluronic acid, or other intraarticular injections of the index knee within 3 months of screening and/or not willing to abstain from treatments for the duration of the study

• Received long acting hyaluronic acid injection of the index knee within 6 months of screening and/or not willing to abstain from treatments for the duration of the study.

• History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, amyloidosis or fibromyalgia.

• Clinical signs and symptoms of active knee infection or radiographic evidence of crystal disease other than chondrocalcinosis (i.e., gout and CPPD).

• A history of abnormal laboratory results =2.5 x ULN indicative of any significant medical disease, which in the opinion of the investigator, would preclude the subjects participation in the study

• Any of the following abnormal laboratory results during screening:

1. ALT and AST =2.5x ULN

2. Hemoglobin <11.5 g/dL (Female) or <13.2 g/dL (Male)

3. WBC <3500 cells/mm3

4. Lymphocyte count =1000 cells/mm3

5. Serum creatinine =1.5 x ULN

6. Platelet count below the central laboratory lower limit of normal.

• History of malignancy in the past ten years (<10 years), with the exception of resected basal cell, squamous cell of the skin, resected cervical atypia or carcinoma in situ.

• Significant hip pain, ipsilateral to the index knee that may interfere with assessments of index knee pain

• Skin breakdown at the knee where the injection would take place

• A known or clinically suspected infection with human immunodeficiency virus (HIV), or hepatitis C or B viruses

• Participated within 3 months or will participate concurrently in another investigational drug or vaccine study

• A history of drug or alcohol dependence or abuse in the past 3 years

• Previous treatment with BMP-7 or any bone morphogenetic protein

• A female with reproductive capability who is unwilling to use birth control for the duration of the study and/or intends to conceive within 12 months of dosing.

• Other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis of the Knee
• Osteoarthritis, Knee

Intervention

Drug:
• Bone morphogenetic protein 7
Comparison of different doses of the drug via single intraarticular knee injection
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Johns Hopkins Medical Center	Baltimore	Maryland
United States	Billings Clinic	Billings	Montana
United States	Rheumatology Associates of S. Florida	Boca Raton	Florida
United States	Boulder Medical Center, PC	Boulder	Colorado
United States	Apex Medical Research, AMR, Inc	Chicago	Illinois
United States	Northwestern Center for Clinical Research	Chicago	Illinois
United States	The Ohio State University Medical Center	Columbus	Ohio
United States	Klein & Associates, MD, PA	Cumberland	Maryland
United States	Baylor Research Institute	Dallas	Texas
United States	Altoona Center for Clinical Research	Duncansville	Pennsylvania
United States	Arthritis and Osteoporosis Center of Maryland	Frederick	Maryland
United States	Arizona Arthritis and Rheumatology Research	Glendale	Arizona
United States	Houston Institute for Clinical Research	Houston	Texas
United States	Houston Medical Research Associates	Houston	Texas
United States	The Center for Pharmaceutical Research, PC	Kansas City	Missouri
United States	David R. Mandel, MD, Inc.	Mayfield Village	Ohio
United States	Illinois Bone and Joint Institute	Morton Grove	Illinois
United States	The Arthritis Center	Palm Harbor	Florida
United States	Stanford University School of Medicine	Palo Alto	California
United States	UC Davis Medical Center, Center for Aging	Sacramento	California
United States	Rheumatology Associates	Stuart	Florida
United States	Tacoma Center for Arthritis Research	Tacoma	Washington
United States	University of Arizona Arthritis Center	Tucson	Arizona
United States	Robin Dore, MD, Inc	Tustin	California
United States	Clinical Research Center of Reading	West Reading	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Stryker Biotech

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.		Baseline, and at 24 weeks	No